Being prescribed semaglutide, the active ingredient in Ozempic and Wegovy, increases a person’s chance of developing a sight-threatening condition, a Harvard study published on Wednesday found.
The JAMA Network Open study found that diabetic patients prescribed semaglutide had more than four times the chance of developing non-arteritic anterior ischemic optic neuropathy when compared to other diabetic patients.
